These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32226939)

  • 1. A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond
    Altmann A; Scelsi MA; Shoai M; de Silva E; Aksman LM; Cash DM; Hardy J; Schott JM
    Brain Commun; 2020; 2(1):fcz047. PubMed ID: 32226939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
    Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
    Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considering the APOE locus in Alzheimer's disease polygenic scores in the Health and Retirement Study: a longitudinal panel study.
    Ware EB; Faul JD; Mitchell CM; Bakulski KM
    BMC Med Genomics; 2020 Nov; 13(1):164. PubMed ID: 33143703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.
    Tan CH; Bonham LW; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Yokoyama JS; Rabinovici GD; Miller BL; Yaffe K; Schellenberg GD; Kauppi K; Holland D; McEvoy LK; Kukull WA; Tosun D; Weiner MW; Sperling RA; Bennett DA; Hyman BT; Andreassen OA; Dale AM; Desikan RS;
    Brain; 2019 Feb; 142(2):460-470. PubMed ID: 30689776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polygenic coronary artery disease association with brain atrophy in the cognitively impaired.
    de Silva E; Sudre CH; Barnes J; Scelsi MA; Altmann A;
    Brain Commun; 2022; 4(6):fcac314. PubMed ID: 36523268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.
    Martiskainen H; Helisalmi S; Viswanathan J; Kurki M; Hall A; Herukka SK; Sarajärvi T; Natunen T; Kurkinen KM; Huovinen J; Mäkinen P; Laitinen M; Koivisto AM; Mattila KM; Lehtimäki T; Remes AM; Leinonen V; Haapasalo A; Soininen H; Hiltunen M
    J Alzheimers Dis; 2015; 43(2):565-73. PubMed ID: 25096612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards cascading genetic risk in Alzheimer's disease.
    Altmann A; Aksman LM; Oxtoby NP; Young A; ; Alexander DC; Barkhof F; Shoai M; Hardy J; Schott JM
    Brain; 2024 May; ():. PubMed ID: 38820112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.
    Nho K; Kim S; Horgusluoglu E; Risacher SL; Shen L; Kim D; Lee S; Foroud T; Shaw LM; Trojanowski JQ; Aisen PS; Petersen RC; Jack CR; Weiner MW; Green RC; Toga AW; Saykin AJ;
    BMC Med Genomics; 2017 May; 10(Suppl 1):29. PubMed ID: 28589856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer's Disease.
    Hohman TJ; Dumitrescu L; Oksol A; Wagener M; Gifford KA; Jefferson AL;
    PLoS One; 2017; 12(11):e0188501. PubMed ID: 29190651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linear Mixed Model Analysis of Polygenic Hazard Score on Verbal Memory Decline in Alzheimer's Disease.
    Wang K; Xu C; Theeke LA; Xiao D; Luo X; Xie C;
    Nurs Res; 2023 Jan-Feb 01; 72(1):66-73. PubMed ID: 36097266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic risk for Alzheimer's disease influences neuropathology via multiple biological pathways.
    Hannon E; Shireby GL; Brookes K; Attems J; Sims R; Cairns NJ; Love S; Thomas AJ; Morgan K; Francis PT; Mill J
    Brain Commun; 2020; 2(2):fcaa167. PubMed ID: 33376986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease.
    Porter T; Burnham SC; Savage G; Lim YY; Maruff P; Milicic L; Peretti M; Ames D; Masters CL; Martins RN; Rainey-Smith S; Rowe CC; Salvado O; Taddei K; Groth D; Verdile G; Villemagne VL; Laws SM
    Front Aging Neurosci; 2018; 10():423. PubMed ID: 30620773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid biomarkers for Alzheimer's disease: the role of apolipoprotein E genotype, age, and sex.
    Mehrabian S; Alexopoulos P; Ortner M; Traykov L; Grimmer T; Kurz A; Förstl H; Bickel H; Diehl-Schmid J
    Neuropsychiatr Dis Treat; 2015; 11():3105-10. PubMed ID: 26719695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathway-specific polygenic scores for Alzheimer's disease are associated with changes in brain structure in younger and older adults.
    Harrison JR; Foley SF; Baker E; Bracher-Smith M; Holmans P; Stergiakouli E; Linden DEJ; Caseras X; Jones DK; Escott-Price V
    Brain Commun; 2023; 5(5):fcad229. PubMed ID: 37744023
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.